Trident Texofab Ltd is Rated Sell

Jan 05 2026 10:15 AM IST
share
Share Via
Trident Texofab Ltd is rated 'Sell' by MarketsMojo, with this rating last updated on 03 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.



Current Rating and Its Implications for Investors


The 'Sell' rating assigned to Trident Texofab Ltd indicates a cautious stance for investors considering this microcap stock in the Garments & Apparels sector. This recommendation suggests that the stock may underperform relative to the broader market or its peers over the near to medium term. Investors should weigh this rating carefully, understanding that it is based on a comprehensive evaluation of multiple factors that influence the company’s prospects.



Here’s How the Stock Looks Today


As of 05 January 2026, Trident Texofab Ltd’s Mojo Score stands at 44.0, placing it firmly in the 'Sell' category. This score reflects a decline of 6 points from the previous 50, which corresponded to a 'Hold' rating before 03 December 2025. The stock’s day change on this date was +0.73%, with a one-year return of +44.01%, indicating some recent positive price momentum despite the cautious rating.



Quality Assessment


The company’s quality grade is below average, signalling concerns about its long-term fundamental strength. The average Return on Capital Employed (ROCE) is 6.88%, which is modest and suggests limited efficiency in generating profits from its capital base. Additionally, the company’s high Debt to EBITDA ratio of 6.83 times points to a significant debt burden, raising questions about its ability to service liabilities comfortably. This financial leverage could constrain future growth and increase risk for shareholders.



Valuation Considerations


Trident Texofab Ltd is currently considered expensive based on valuation metrics. The ROCE of 7.4% combined with an Enterprise Value to Capital Employed ratio of 4.6 indicates that the stock is trading at a premium relative to its capital base. However, it is noteworthy that the stock trades at a discount compared to its peers’ average historical valuations, which may offer some relative value. The company’s PEG ratio is notably high at 13.9, reflecting that the stock price may be pricing in substantial future earnings growth, which could be challenging to sustain.




Register here to know the latest call on Trident Texofab Ltd



  • - Fundamental Analysis

  • - Technical Signals

  • - Peer Comparison


Register Now →




Financial Trend and Profitability


The financial grade for Trident Texofab Ltd is positive, reflecting encouraging trends in profitability and earnings growth. Over the past year, the company’s profits have risen by 62.6%, a robust increase that outpaces the stock’s 44.01% return over the same period. This suggests that while the stock price has appreciated significantly, the underlying earnings growth has been even stronger, which is a positive sign for long-term investors. However, the high PEG ratio tempers enthusiasm, implying that the market may already be pricing in this growth.



Technical Outlook


Technically, the stock is mildly bullish, indicating some positive momentum in price action. Short-term returns show mixed performance, with a 1-week gain of 5.72% and a 6-month gain of 18.81%, but recent monthly and quarterly returns have been negative, at -23.44% and -24.90% respectively. This volatility suggests that while there is some buying interest, the stock remains susceptible to fluctuations and may not yet have established a sustained upward trend.



Summary for Investors


In summary, Trident Texofab Ltd’s 'Sell' rating reflects a combination of below-average quality, expensive valuation, positive but potentially over-optimistic financial trends, and a mildly bullish technical stance. Investors should consider these factors carefully, recognising that the company faces challenges related to debt and valuation, even as it demonstrates strong profit growth. The rating advises caution, particularly for those seeking stable, low-risk investments in the Garments & Apparels sector.




Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.



  • - Investment Committee approved

  • - 50+ candidates screened

  • - Strong post-announcement performance


See Why It Was Chosen →




Investor Takeaway


For investors evaluating Trident Texofab Ltd, it is essential to balance the company’s recent profit growth and positive financial trends against its high leverage and valuation concerns. The 'Sell' rating serves as a prudent reminder to approach this stock with caution, particularly given its microcap status and sector volatility. Monitoring ongoing financial performance and market conditions will be crucial for those holding or considering this stock in their portfolios.






{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Why is Trident Texofab Ltd falling/rising?
Dec 27 2025 12:48 AM IST
share
Share Via
Trident Texofab Ltd is Rated Sell
Dec 25 2025 12:58 PM IST
share
Share Via
Is Trident Texofab overvalued or undervalued?
Dec 05 2025 08:41 AM IST
share
Share Via
Is Trident Texofab technically bullish or bearish?
Dec 04 2025 08:47 AM IST
share
Share Via
How has been the historical performance of Trident Texofab?
Dec 03 2025 10:55 PM IST
share
Share Via